Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in Mice

Immunotherapy with anti-CD20-specific antibodies (rituximab), has become the standard of care for B cell lymphoproliferative disorders and many autoimmune diseases. In rheumatological patients the effect of rituximab on bone mass yielded conflicting results, while in lymphoma patients it has not yet...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Immunol
Asıl Yazarlar: Kolomansky, Albert, Kaye, Irit, Ben-Califa, Nathalie, Gorodov, Anton, Awida, Zamzam, Sadovnic, Ofer, Ibrahim, Maria, Liron, Tamar, Hiram-Bab, Sahar, Oster, Howard S., Sarid, Nadav, Perry, Chava, Gabet, Yankel, Mittelman, Moshe, Neumann, Drorit
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2020
Konular:
Immunology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7604358/
https://ncbi.nlm.nih.gov/pubmed/33193330
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.561294
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller